Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities-law violations by EyePoint, Inc. on behalf of investors who purchased or acquired the company’s securities and suffered significant losses. EyePoint said on Aug. 17, 2026, that its LUGANO Phase 3 trial of DURAVYU, an intravitreal insert for wet age-related macular degeneration, did not meet its prespecified primary endpoint for change in best-corrected visual acuity versus on-label aflibercept. EyePoint’s stock fell more than 66% after the disclosure. The law firm is inviting affected investors to provide information about their losses at no cost or obligation, while noting that the investigation does not establish wrongdoing or guarantee a recovery.